Member Info for P3T3R

"Why not tell us news like that officially. For me it's important that we are clearly applying or have applied for ISO15189 accreditation ..."

"There have been lots of rns's, but I'm afraid it's about quality not quantity ..."

And an RNS about applying for xxxxxx accreditation (if indeed we have) is going to add to the quality pile ... get a grip ... ROFLMAO ...

"Contact YGEN directly with these comments and see what response you get. Then you can relay them back on here ..."

The only thing that really irritated me enough to contact Investor Relations was LR's comment on Elucigene growth (+12% after a flat 3 years), when it totally contradicted Mark Street-Docherty press statements as Elucigene CEO prior to being acquired (+28/30%).

Response was that they could not comment on other companies press releases, but could confirm that LR comments was based upon our own due diligence.

Having gone back to the RNS 17 Apr 2019 "Proposed Acquisition" it does state Elucigene income statement as £3.0m/£3.6m/£3.6m for the prior 3 years so LR comments do actually ring true according to our own previous RNSs/due diligence. I now suspect that MS-D was in fact talking up his company in the way that many on this board wish that LR would now do.
.
.
I think a lot of problems arise when we deviate from what we have actually been told and start to fantasize about alternate realities.
.
.
hTTps://www.med-technews.com/features/elucigene-diagnostics-on-exporting-around-the-world/
"The average industry revenue growth for UK companies working in in vitro diagnostics stands at 7%. For the last two years, Elucigene has outstripped that by a factor of four."

hTTp://www.drugdiscoverytoday.com/view/47480/by-royal-approval-queen-s-award-success-for-elucigene/
"Revenues have grown around 30% in each of the last two years and are currently 20% ahead this financial year."

This sentence from the book that I am currently reading sums it all up really ...

"Research shows that people (like other animals) often prefer small, immediate rewards to larger rewards in the future ..."

- Micheal J Mauboussin, "More than you know"

"I think you are deluded sir, thinking of multi bags with Ygen ..."

You are of course entitled to your opinion ...

All depends on your timescales of course ... In the meantime, personally, I am not losing sleep at night ...

"If a TO came along at 30p I and I suspect the vast majority of PI's would bite that hand off ..."

Absolutely typical UK investor short termist ... grab a couple of pence in the present and forego the future ... seen it so many times ...

Good find NiptSteve ...

Would be better if everyone invested based upon what they know and not what they hope for reading between the lines ... LOL

Govt tenders that they expect to win ...

I thought I heard the words they were talking rather than expect to win ... big difference ... be nice to be proved wrong.

"My point on staff numbers/ salaries etc this rightly or wrongly is a strong concern of mine ..."

If you work through the annual reports and do the calculations, £revenue/employee has been rising at a CAGR of over 20% a year since 2016 after the IONA test was monetised. 2015 and prior I think revenues were mostly grants/research and not really relevant.

If you are assuming +20 staff this year, and they meet (or close to) forecast numbers then the trend continues and even improves slightly. I make it £162.2k/employee for 2021 ...

"All listed companies in the world have buyers and sellers.."

Exactly.

Some make profits. Some do not. Some go up. Some go down.

For a company that makes NO PROFIT we are not doing too badly. All IMHO of course

AIM All-Share
1-year 999/888 112.5%
02-Jan 999/963 103.7%

YGEN
1-year 16.73/13.00 128.8%
02-Jan 16.75/13.88 120.7%

Not sure what I am waiting for next from Ygen ...

“The big money is not in the buying or selling, but in the waiting.” - Charlie Munger

hTTps://www.motilaloswalmf.com/knowledge-centre/5-keys-of-investing/5-key-quotes-by-charlie-munger-on-value-investing-and-creating-wealth/69

My understanding is that the 250 machines target was somehow tied in to their earnouts for FY23 ... not totally clear, but that is how I interpret it ...

"In August this year we bought Coastal Genomics. It's patented machines had the ability to multiply DNA sample preparation for IONA nx and Covid-19 testing capacity."

This was clarified at Question 1 in the Investor Presentation.
The Coastal Genomics technology will be used in conjuction with NGS platforms only. Covid-19 testing is PCR and using the CG tech will not provide added value apparently.

"But NEVER pump the company like other AIM ones do? I have lost all respect for them."

I think this single statement says it all really ... All IMHO

https://www.sharesmagazine.co.uk/news/shares/yourgene-health-sees-stronger-second-half-ahead

"Completely anti climax as I am now starting to expect since locked into this stock."

No one is "locked into this stock" ... it's a choice that you choose to make ...

"Consensus forecast was for 25 mill. That consensus figure didn't even include any covid bonus, so which ever way you look at it from purely a figures perspective it is a terrible performance."

Not true.

I think you will find that consensus 2021 forecast (Walbrook) was originally £22.3m (Aug) and then increased by £3m in Sept to £25.3m (6 mths covid).

Align Research forecast £21.3m for 2021 (Aug) without covid contribution.

Exactly Pacman1 ... and the start of the AMS run-up was when they were waiting for and eventually received FDA for Liquiband and started being able to market their wares in the US ... sounds familiar.

Align Research assumes £42 per test providing an annualised £5m for 10k per month.

http://www.alignresearch.co.uk/cpt-company/yourgene-health/

I took it as a passing reference that it had been looked at ... certainly not a commitment as such ... I may be wrong as I often am , LOL